Australian Researchers Found a Breakthrough Drug That Beats the Crap Out of Leukemia

Source: Getty Images
Source: Getty Images

A new drug could be a major breakthrough in the fight against cancer.

If leukemia is Popeye, BCL-2 is its spinach. It's a protein in the body that makes chronic lymphocytic leukemia, or CLL, grow. And now, researchers say, a new drug called Venetoclax, recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration, could effectively target BCL-2. 

So far, the medication looks effective. A study, published in the New England Journal of Medicine, observed 116 patients with advanced chronic lymphocytic leukemia and found cancer was reduced with Venetoclax in 80% of cases. Those patients had already undergone multiple treatment methods, including chemotherapy, with minor rates of success.

Finding a successful way to attack the BCL-2 protein could make Venetoclax a cancer-fighting game-changer. "If you have too much BCL-2, it prevents cells from dying appropriately," Dr. Michael Grossbard, director of the Hematologic Malignancies Clinical Program at the Laura & Isaac Perlmutter Cancer Center at NYU Langone Medical Center, told Mic. "In CLL, there's an overexpression of that protein so the cells don't die, and then they accumulate. That's what leads to the accumulation of CLL."

Leukemia blood cells
Source: 
Getty Images

"There is no other drug or medicine previously available that has had the ability to inhibit this BCL-2 protein," said professor John Seymour, a lead researcher on the study, according to the Sydney Morning Herald. "That potential for broader application, and the fact that this is a completely new class of drugs, takes this beyond simply being a very good outcome for patients."

While the hype of a "miracle drug" that "melts away" cancer cells might be a little overblown, Grossbard told Mic, this is an exciting development in the cancer field, one that can be added to a few other up-and-comers. "It's a good drug, but I wouldn't neglect that you could've said the same for Zydelig and another called Imbruvica, both of which also showed high response rates in CLL patients," Grossbard said.

"Which of these will turn out to be most effective and have the largest side effect profile remains to be seen."

How likely are you to make Mic your go-to news source?

Max Plenke

Max Plenke is a staff writer at Mic, where he covers breaking news, climate science, health and the future. His work has appeared in Esquire, GQ and Wallpaper. Send story tips to max@mic.com.

MORE FROM

Car slams into Eid celebrants in UK, injuring 6; police say terrorism isn't suspected

Police say they believe an Eid celebrant was behind the wheel of the car that injured six outside a mosque.

Oil truck explodes in Pakistan, killing at least 153

The deadly fire broke out as residents rushed to collect the leaking oil from the overturned tanker.

Will Justice Anthony Kennedy retire at end of Supreme Court term? Here's what we know.

Rumors that the 80-year-old swing justice may leave the bench are fueling fear of a second Trump pick on the nation's high court.

3 states and D.C. allow same flammable building materials behind Grenfell Tower fire

The causes of London's Grenfell Tower are similar to the justifications used to waive fire regulations in the U.S.

New Jersey bill would require kids to be taught how to interact with police

Students from kindergarten through 12th grade would receive the education.

UK Parliament hit with cyberattack

Members of Parliament had difficulty accessing their emails Saturday in the wake of the attack.

Car slams into Eid celebrants in UK, injuring 6; police say terrorism isn't suspected

Police say they believe an Eid celebrant was behind the wheel of the car that injured six outside a mosque.

Oil truck explodes in Pakistan, killing at least 153

The deadly fire broke out as residents rushed to collect the leaking oil from the overturned tanker.

Will Justice Anthony Kennedy retire at end of Supreme Court term? Here's what we know.

Rumors that the 80-year-old swing justice may leave the bench are fueling fear of a second Trump pick on the nation's high court.

3 states and D.C. allow same flammable building materials behind Grenfell Tower fire

The causes of London's Grenfell Tower are similar to the justifications used to waive fire regulations in the U.S.

New Jersey bill would require kids to be taught how to interact with police

Students from kindergarten through 12th grade would receive the education.

UK Parliament hit with cyberattack

Members of Parliament had difficulty accessing their emails Saturday in the wake of the attack.